Patient and physician-reported outcomes with tirbanibulin 1% ointment for actinic keratosis under conditions close to routine clinical practice in Spain and Italy (TIRBASKIN study)
Background: The objective was to evaluate patient- and physician-reported outcomes following treatment with tirbanibulin ointment 1% once daily for 5 consecutive days for actinic keratoses (AKs) under conditions close to routine clinical practice in Spain and Italy.
Authors
- Oriol Yélamos (ORCID: https://orcid.org/0000-0002-8058-3095)
- Yolanda Gilaberte (ORCID: https://orcid.org/0000-0001-8034-3617)
- Andrea Conti (ORCID: https://orcid.org/0000-0003-4848-3817)
- Anna Lecchi (ORCID: https://orcid.org/0000-0002-5730-4473)
- Marco Romanelli (ORCID: https://orcid.org/0000-0002-4127-0141)
- C. Serra‐Guillén (ORCID: https://orcid.org/0000-0002-0410-9631)
- Javier Cañueto (ORCID: https://orcid.org/0000-0003-0037-7353)
- B. Kostov
- F. Pajuelo (ORCID: https://orcid.org/0000-0001-8339-2406)
- V. Cappello
Institutions
- Hospital de Sant Pau (ES)
- Ospedale Santa Chiara (IT)
- Complejo Hospitalario de Salamanca (ES)
- Fundación Instituto Valenciano de Oncología (ES)
- Hospital Universitario Miguel Servet (ES)
- Almirall (Spain) (ES)
- Ospedale Infermi di Rimini (IT)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100300
- Citations
- 1
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35